<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35584898</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1472-3263</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>18</Day>
            </PubDate>
          </JournalIssue>
          <Title>Sexually transmitted infections</Title>
          <ISOAbbreviation>Sex Transm Infect</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Can we screen less frequently for STI among PrEP users? Assessing the effect of biannual STI screening on timing of diagnosis and transmission risk in the AMPrEP Study.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">sextrans-2022-055439</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1136/sextrans-2022-055439</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In many countries, HIV pre-exposure prophylaxis (PrEP) users are screened quarterly for STIs. We assessed the consequences of less frequent STI testing. We also assessed determinants of asymptomatic STI and potential for onward transmission.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Using data from the AMPrEP study, we assessed the proportion of syphilis, and genital, anal, and pharyngeal chlamydia and gonorrhoea diagnoses which would have been delayed with biannual versus quarterly screening. We assessed the potential for onward transmission by examining reported condomless anal sex (CAS) in periods after to-be-omitted visits when screening biannually. We assessed determinants of incident asymptomatic STIs using Poisson regression and calculated individual risk scores on the basis of the coefficients from this model.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">We included 366 participants. Median follow-up was 47 months (IQR 43-50). 1,183STIs were diagnosed, of which 932(79%) asymptomatic. With biannual screening, 483 asymptomatic STIs (52%) diagnoses would have been delayed at 364 study visits. Of these visits, 129 (35%), 240 (66%) and 265 (73%) were followed by periods of CAS with steady, known casual or unknown casual partners, respectively. Older participants had a lower risk of asymptomatic STI (incidence rate ratio (IRR) 0.86/10-year increase, 95% CI 0.80 to 0.92), while CAS with known (IRR 1.36, 95% CI 1.10 to 1.68) and unknown (IRR 1.86, 95% CI 1.48 to 2.34) casual partners and chemsex (IRR 1.51, 95% CI 1.28 to 1.78) increased the risk. The individual risk scores had limited predictive value (sensitivity=0.70 (95% CI 0.66 to 0.74), specificity=0.50 (95% CI 0.48 to 0.51)).</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Reducing the STI screening frequency to biannually among PrEP users will likely result in delayed diagnoses, potentially driving onward transmission. Although determinants for asymptomatic STIs were identified, predictive power was low.</AbstractText>
          <CopyrightInformation>Â© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Jongen</LastName>
            <ForeName>Vita W</ForeName>
            <Initials>VW</Initials>
            <Identifier Source="ORCID">0000-0001-9538-1501</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands vjongen@ggd.amsterdam.nl.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zimmermann</LastName>
            <ForeName>Hanne M L</ForeName>
            <Initials>HML</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Work and Social Psychology, Maastricht University, Maastricht, Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Goedhart</LastName>
            <ForeName>Marit</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bogaards</LastName>
            <ForeName>Johannes A</ForeName>
            <Initials>JA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Epidemiology &amp; Data Science, Amsterdam UMC, Vrije Universiteit Amsterdam, location VUmc, Amsterdam, Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Davidovich</LastName>
            <ForeName>Udi</ForeName>
            <Initials>U</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Social Psychology, University of Amsterdam, Amsterdam, Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Coyer</LastName>
            <ForeName>Liza</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Amsterdam UMC, University of Amsterdam, Internal Medicine, Amsterdam Infection and Immunity (AII), Amsterdam, Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>de Vries</LastName>
            <ForeName>Henry J C</ForeName>
            <Initials>HJC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Amsterdam UMC, University of Amsterdam, Department of Dermatology, Amsterdam Infection and Immunity (AII), location Academic Medical Centre, Amsterdam, Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Prins</LastName>
            <ForeName>Maria</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Amsterdam UMC, University of Amsterdam, Internal Medicine, Amsterdam Infection and Immunity (AII), Amsterdam, Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hoornenborg</LastName>
            <ForeName>Elske</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schim van der Loeff</LastName>
            <ForeName>Maarten F</ForeName>
            <Initials>MF</Initials>
            <Identifier Source="ORCID">0000-0002-4903-7002</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Amsterdam UMC, University of Amsterdam, Internal Medicine, Amsterdam Infection and Immunity (AII), Amsterdam, Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <CollectiveName>Amsterdam PrEP Project team in the HIV Transmission Elimination Amsterdam (H-TEAM) Initiative</CollectiveName>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>18</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Sex Transm Infect</MedlineTA>
        <NlmUniqueID>9805554</NlmUniqueID>
        <ISSNLinking>1368-4973</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Chlamydia Infections</Keyword>
        <Keyword MajorTopicYN="N">NEISSERIA GONORRHOEAE</Keyword>
        <Keyword MajorTopicYN="N">PREP</Keyword>
        <Keyword MajorTopicYN="N">Pre-Exposure Prophylaxis</Keyword>
        <Keyword MajorTopicYN="N">SYPHILIS</Keyword>
      </KeywordList>
      <CoiStatement>Competing interests: The Public Health Service of Amsterdam received the drugs for the Amsterdam PrEP Study from Gilead Sciences based on an unconditional grant. UD received unrestricted research grants and speaker fees from Gilead Sciences, paid to his institute. HdV received grants from Medigene, and advisory board and speaker fees from Gilead Sciences, Medigene, Abbvie, Janssen-Cilag and Willpharma, all paid to his institute. MP received unrestricted research grants and speaker fees from Gilead Sciences, Roche, Abbvie and MSD, all paid to her institute. All other authors declare no competing interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>21</Hour>
          <Minute>2</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35584898</ArticleId>
        <ArticleId IdType="doi">10.1136/sextrans-2022-055439</ArticleId>
        <ArticleId IdType="pii">sextrans-2022-055439</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
